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Abstract
Background: Africa has the highest burden of Sickle cell disease (SCD) but there are few large, systematic studies
providing reliable descriptions of the disease spectrum. Tanzania, with 11,000 SCD births annually, established the
Muhimbili Sickle Cell program aiming to improve understanding of SCD in Africa. We report the profile of SCD seen
in the first 10 years at Muhimbili National Hospital (MNH).
Methods: Individuals seen at MNH known or suspected to have SCD were enrolled at clinic and laboratory testing
for SCD, haematological and biochemical analyses done. Ethnicity was self-reported. Clinical and laboratory features
of SCD were documented. Comparison was made with non-SCD population as well as within 3 different age
groups (< 5, 5–17 and ≥ 18 years) within the SCD population.
Results: From 2004 to 2013, 6397 individuals, 3751 (58.6%) SCD patients, were enrolled, the majority (47.4%) in age
group 5–17 years. There was variation in the geographical distribution of SCD. Individuals with SCD compared to
non-SCD, had significantly lower blood pressure and peripheral oxygen saturation (SpO2). SCD patients had higher
prevalence of severe anemia, jaundice and desaturation (SpO2 < 95%) as well as higher levels of reticulocytes, white
blood cells, platelets and fetal hemoglobin. The main causes of hospitalization for SCD within a 12-month period
preceding enrolment were pain (adults), and fever and severe anemia (children). When clinical and laboratory
features were compared in SCD within 3 age groups, there was a progressive decrease in the prevalence of splenic
enlargement and an increase in prevalence of jaundice. Furthermore, there were significant differences with
monotonic trends across age groups in SpO2, hematological and biochemical parameters.
Conclusion: This report confirms that the wide spectrum of clinical expression of SCD observed elsewhere is also
present in Tanzania, with non-uniform geographical distribution across the country. Age-specific analysis is consistent
with different disease-patterns across the lifespan.
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Background
The highest burden of sickle cell disease (SCD) is in Africa
where up to 75% of the 300,000 global births of SCD per
year occur [1] and where childhood mortality remains
high, ranging between 50 and 90% [2]. Much of what is
known about the spectrum of SCD is from cohort studies
in USA [3], Europe and Jamaica [4–6], with few studies
carried out in Africa [7–10] although it is recognized that
there is a need for detailed prospective, epidemiological
studies [11]. Tanzania is amongst the 5 countries in the
world with the highest estimated number of newborns
with SCD a year [12] (Nigeria 85,000, Democratic Repub-
lic of Congo 42,000, India 38,000; Tanzania 11,000 and
Uganda 10,000 [1, 11]). The World Health Organization
(WHO) has formally classified SCD as a major public
health problem [13] and Tanzania, like other African
countries has included SCD as a priority disease condition
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in their strategy for Non-Communicable Diseases (NCD)
[13, 14]. In 2004, Tanzania established the Muhimbili
Sickle cell (MSC) program [15], integrating research and
healthcare in a countrywide referral hospital for all disease
conditions, the Muhimbili National Hospital (MNH). The
main goal was to conduct research that would delineate
the spectrum of disease, identify the main causes of
morbidity and mortality and provide evidence-based
knowledge that would improve healthcare through the
introduction of locally-appropriate interventions and
policies. Preliminary information on this population,
particularly mortality rates [16], rates and risk factors
for malaria [17, 18], bacterial infections [19] and other
important clinical features [20–23] has been published.
The MSC program has also provided a platform to con-
duct studies to describe genetic determinants of clinical
disease [24], successfully conducting one of the first
genome-wide association studies in SCD in Africa [25].
In this paper, we outline the profile of the cohort in
the MSC program enrolled over the first 10 years. We
then describe the clinical and laboratory features of the
SCD population enrolled, as well as the geographical dis-
tribution, based on self-reported ethnicity. This program
demonstrates the feasibility of conducting longitudinal,
cohort studies in Africa and this baseline report is set-
ting the stage for further detailed description of the
course and spectrum of disease over time.
Methods
Study site
Tanzania has a population of 45 million and is classified
as a low income country. The MSC program was estab-
lished through collaboration between Muhimbili Univer-
sity of Health and Allied Sciences (MUHAS), the oldest
and largest biomedical university in Tanzania and MNH,
the national referral hospital which is in Dar-es-Salaam
on the Eastern coast.
Study population
Individuals attending MNH who were known or sus-
pected clinically to have SCD or related to SCD individ-
uals were invited to the clinic for enrolment.
Clinic procedures
The hospital had two clinics a week for SCD patients.
During the course of the program, a third clinic was
started. Patients were encouraged to visit the clinic in
the event of an acute illness. All individuals who were
enrolled were given a unique identifier number and hos-
pital case number. Case report forms (CRF) were com-
pleted including demographic, clinical history and
physical examinations. Residence information, including
telephone number and consent to contact the family in
case the patients did not attend clinic for more than
9 months were obtained. Management of SCD followed
hospital guidelines which included prescription of folic
acid 5 mg/day, investigations to identify underlying add-
itional causes of anaemia, blood transfusion (BT) for
those with haemoglobin< 5 g/dL, or heart failure. Indi-
viduals with splenomegaly requiring BT (> 3 times a
year) were referred for splenectomy. Oral iron was pre-
scribed to those with iron deficiency, defined by low
serum ferritin or empirically to those with low MCV
(< 80 fl) and MCHC (< 25 g/dL). Use of insecticide
treated nets was emphasized to prevent malaria infec-
tions and chloroquine prophylaxis was prescribed until
its use was discontinued due to high resistance. From
2010, SCD children under 5 years of age were pre-
scribed daily oral penicillin.
Laboratory procedures
At enrolment visits, peripheral blood samples in EDTA
were analyzed for full blood count (haemoglobin (Hb),
red blood cell count (RBC), mean corpuscular volume
(MCV), mean corpuscular haemoglobin (MCH), mean
corpuscular haemoglobin Concentration (MCHC)],
white blood cell (WBC) and platelet count (PLT) (Pentra
60, Horiba ABX, Kyoto, Japan; Sysmex XT2000i, Hyogo,
Japan). Nucleated RBC could not be differentiated from
neutrophils by the haematology analyzer. Reticulocyte
count (New methylene blue method; Sysmex XT2000i,
Hyogo, Japan) and fetal haemoglobin (HbF) levels by
High performance Liquid Chromatography (HPLC)
(BioRad, Hercules, CA, USA) were obtained. SCD diag-
nosis was made by HPLC and Haemoglobin electrophor-
esis (Helena, Sunderland, Tyne & Wear, UK). Bilirubin
total (BIL-T), bilirubin direct (BIL-D)], lactate dehydro-
genase (LDH), alkaline phosphatase (ALP) and creatinine
were assayed using a chemistry analyzer (Roche Cobas
Mira, New York, USA or Abbott Architect, New York,
USA). Daytime peripheral oxygen saturation (SpO2) was
determined using a pulse oximeter (pulse oximetry;
Nellcor, Pleasanton, CA, USA). Peripheral Oxygen de-
saturation was defined as < 95%.
Data management and analysis
Data were managed using MySQL database (Sun
Microsystems Inc., Santa Clara, California, USA). Ana-
lysis was performed using STATA and R statistical soft-
ware (http://www.R-project.org/). Continuous variables
with normal distribution were compared using t-test or
ANOVA test and skewed continuous variables were
compared using Wilcoxon sign rank or Kruskal Wallis
tests, while categorical data were compared using chi-
square tests. In order to evaluate the trend of different la-
boratory parameters, the mean difference between non-
SCD and SCD were compared across the age groups.
Some mean differences were log transformed to improve
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visibility of parameters with high and low levels of the dif-
ference. Weighted logistic regression was used to deter-
mine association between binary response variable and
explanatory variables (clinical and haematological factors)
accounting for under representation of non-SCD indi-
viduals. A p-value < 0.05 was considered to be statisti-
cally significant.
Description of the MSC cohort
The description included the age structure and pattern
of enrollment. SCD diagnoses were classified into 2 cat-
egories: SCD was for SS and non-SCD for those with AS
and AA. SCD were almost all βS/βS with a small fraction
of S/β0 thalassaemia (estimated at 4% - unpublished
data) and very rare βS/HPFH. SC or CC disease was not
encountered. The age of patients was calculated at date
of visit from the date of birth and three age group cat-
egories were defined: < 5, 5–17 and ≥ 18 (adults) years.
Description of clinical and laboratory features between
SCD and non-SCD individuals was limited to individuals
in age group 5–17 years for the following reasons; 1)
< 5 years age group is subject to considerable physio-
logical changes; 2) ≥18 years age group is a heteroge-
neous group and it is not clear whether it consists of
individuals with mild disease who have survived the
early mortality of severe disease but who are symptomatic
and therefore attend MNH for healthcare. The ethnic
group of an individual was from self-reported ethnicity
which is patrilineal. If this information was missing, the
ethnic group of the mother was used. We plotted the geo-
graphical distribution of SCD in Tanzania based on the
ethnicity of the SCD cases registered at MNH. The region
where a particular ethnic group resides was used as a
surrogate for the geographical distribution of SCD.
Geographical coordinates of Tanzania and regional ad-
ministrative boundaries were obtained from Global
administrative boundaries website [26].
Results
During the 10-year period (2004–2013), 6397 individuals
were enrolled, with 3751 (58.6%) having SCD (> 95%
βS/ βS). 3175 (49.6%) were male and 2393 (37.4%) were
children aged < 5 years (Table 1). The median age at
testing was higher in non-SCD than in SCD individuals
(p < 0.001), while the sex ratio was similar between the
two groups and there was no difference among those
who were coming outside Dar (proxy for distance)
compared to those coming from outside Dar es Salaam
(Table 1). As the MSC program continued there was a
statistically significant (p < 0.001) decrease in age of
SCD individuals enrolled; the median age decreased
from 9.1 years [Interquartile range (IQR): 5.1–14.1] in
the first two years (2004–5) to 5.1 years (IQR: 2.3–11.1)
during the last two years (2012–3).
The trend of enrolment on annual basis for the SCD pa-
tients is shown in Fig. 1a. The largest number of individuals
Table 1 Characteristics of individuals enrolled in the Muhimbili Sickle Cell Programme in Dar-es-Salaam, Tanzania
Variable Total Non-SCD SCD Test statistic
(p-value)
Number screened, n (%) 6397 2646 (41.4) 3751 (58.6)
Median age (IQR) 9.3 (2.7–24.1) 6.9 (3.3–12.8) z = 8.7 (< 0.001)
Age group (%)
0–4 2393 (37.4) 956 (36.1) 1437 (38.3) χ2 = 346.7 (< 0.001)
5–17 2592 (40.5) 813 (30.7) 1779 (47.4)
18+ 1360 (21.3) 842 (31.9) 518 (13.8)
Missing 52 (0.8) 35 (1.3) 17 (0.4)
Sex (%)
Male 3175 (49.6) 1294 (48.9) 1881 (50.1) χ2 = 0.96 (0.328)
Female 3222 (50.4) 1352 (51.1) 1870 (49.9)
Place of birth (%)
Dar es Salaam 3807 (59.5) 1445 (54.6) 2362 (63.0) χ2 = 41.36 (< 0.001)
Others 2478 (38.7) 1143 (43.2) 1335 (35.6)
Missing 112 (1.8) 58 (2.2) 54 (1.4)
Place living
Dar es Salaam 4446 (69.5) 1628 (61.5) 2818 (75.13) χ2 = 1.06 (0.304)
Others 834 (13.0) 321 (12.1) 513 (13.9)
Missing 1117 (17.5) 697 (26.2) 420 (11.2)
Test statistics excluded missing values
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with SCD was enrolled, not surprisingly, during the first
year of the program. Subsequently, the annual number en-
rolled was relatively steady, with the median number en-
rolled per month being 62 (IQR: 18.5–92). On average, the
middle age group (5–17 years) was most abundantly repre-
sented (Fig. 1b). However, the rate of enrollment weighted
for population size was highest amongst the youngest
(< 5 years: Fig. 1c).
Geographical distribution of SCD in Tanzania based on
ethnicity of participant
Enrollment is a composite result of the variable prevalence
of the Hb S gene, of migration patterns to Dar-es-Salaam
and referral practices to MNH. With that proviso, we note
that regions with the highest SCD cases were those along
the coast (> 10 cases per 100,000 people), the North-
Eastern part, which include regions of Coast, Tanga and
Zanzibar and along the Lake Victoria zone (Tabora,
Shinyanga, Kagera and Mara) with prevalence ranging
from 5 to 12 cases per 100,000 people (Fig. 2). In
contrast, Arusha, Manyara, Kilimanjaro and Rukwa re-
gions had the lowest representation of SCD (< 2 cases
per 100,000).
Comparison of clinical and laboratory features of
individuals (5 to 17 years) with and without SCD
Table 2 compares the clinical and laboratory parameters
between non-SCD and SCD individuals aged 5–17 years
for the reasons outlined under Methods section. Com-
pared to non-SCD, the SCD group had statistically sig-
nificant higher pulse rate and mean body temperature,
but lower levels of blood pressure and peripheral oxygen
saturation. The prevalence of low oxygen saturation (<
95%), jaundice and splenomegaly was significantly higher
in SCD than in non-SCD group. Regarding laboratory
features, SCD is a well-defined disease for which there is
no a priori appropriate control group. Comparison of
SCD and non-SCD individuals enrolled in the MSC
programme, we find that all parameters were signifi-
cantly different. The SCD group had a significantly lower
A
B C
Fig. 1 Pattern of enrollment of individuals with SCD over a 10-year period. Bars and line shows the annual enrolment and cumulative number of
enrolment respectively (a). Average number of individuals enrolled per year by age group (b) and rate of enrolment per 100 persons per year by
age group (c)
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Hb (g/dl) (7.4 vs 10.6), alkaline phosphatase and creatin-
ine but higher levels of reticulocyte count, RDW, HbF,
MCV, MCH, WBC, platelet count, total, direct and in-
direct bilirubin, aspartate transaminase, and lactate de-
hydrogenase. Similar trends for parameter levels were
observed even when analysis was extended for all age
groups, Fig. 3. The trends of mean difference were simi-
lar across the age groups, except for MCHC (non-SCD
aged < 5 years had higher levels) and ALP (non-SCD
aged > 18 years had lower levels) when compared to
other groups. Only mean difference for platelets, ALP
and creatinine for children < 5 years were not signifi-
cantly different between the non-SCD and SCD groups
(p > 0.05).
Clinical and laboratory features of SCD patients by age
group
Evaluation of the clinical and laboratory features in three
different age groups within the SCD population is pre-
sented in Table 3 and Fig. 4. There were statistically
significant differences between the three age groups
and interestingly, many of the parameters showed mono-
tonic trends with increasing age. Notably, children aged
0–4 years had a significantly higher pulse rate and
prevalence of palpable spleen, whilst peripheral oxygen
saturation was lower in older SCD patients and preva-
lence of jaundice increased with age. The blood pres-
sure (both systolic and diastolic) was significantly
higher in the older SCD populations. For 1165 patients
(31%), we obtained medical history on the causes of
hospitalization in the 12 month period preceding en-
rollment (Fig. 5). Overall, the three commonest causes
of hospitalization were pain, fever (including malaria)
and severe anemia. Severe anaemia was the leading
cause in children < 18 years (36.9% in 0–4 and 30.7 in
5–17 years), whereas pain was the main cause amongst
adults aged ≥18 years (43.2%). Pain (12.9%), fever
(12.0%) and malaria (11.2%) contributed equally in chil-
dren below 5 years, while in children aged 5–17 years
pain (27.4%) was the second contributing factor. Out of
469 patients who were admitted with symptoms of
severe anaemia as the primary cause, severe anaemia
(hb < 5 g.dL) was confirmed in 13.3% of the patients, 36
(7.7%) had pain, while only one patient had jaundice.
Contrarily, of patients with Hb results (338) among
those admitted with pain as the primary cause, only 11
(3.2%) had confirmed severe anaemia, while only three
(out of 388) had jaundice.
The levels of Hb, MCV, MCH and MCHC showed a
slight but significant upward trend, whereas RDW
Fig. 2 Geographical distribution of risk of sickle cell disease in Tanzania. Note: Prevalence is expressed (per 100,000) as the ratio of individuals
with SCD enrolled in the MSC programme from a particular region to the total population of that region. Ethnicity is self-reported based on
patrilineal tribe
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decreased with age. Reticulocyte counts were elevated in
all age groups but they decreased with age. There were
significant differences in the WBC counts with counts
decreasing with age whereas platelet counts increased
with age. Total, direct and indirect bilirubin all increased
significantly with age (p < 0.001). AST and ALP de-
creased with age, however the decrease was only signifi-
cant for ALP (p < 0.001).
Discussion
This is the first study that provides a description of the
spectrum of SCD in Africa from one of the largest
single-centre SCD cohorts in the world. There has been
relatively limited information about the spectrum of
SCD in Africa when compared to information available
from studies outside Africa. Most large series have been
from the US, Jamaica and Europe which have involved
study populations exceeding 2000 patients with pro-
spective follow up for at least 10 years [4, 27, 28]. In Af-
rica, there has been an increase in the number of similar
studies, although the sample size has been smaller (500
to 1000 individuals) and duration has been shorter (up
to 5 years) [7–9].
In the first two years of the MSC program, most of the
patients enrolled were those already receiving clinical
care at MNH, with the majority in the 5–17 year age
group (Fig. 1b). This was therefore likely to be a survival
cohort and highlighted two unmet needs: the urgency of
newborn screening and of strengthening SCD pediatric
care. The peak of ongoing enrollment was in 2011 that
coincided with optimal number of personnel, weekly clinics
and the doctor to patient ratio. This is also the period that
the MSC program started working with the Ministry of
Health of Tanzania with the aim of strengthening SCD
Table 2 Clinical and laboratory features of SCD and non-SCD individuals aged 5–17 years
Non-SCD (HbAA, AS) SCD (HbSS) Test statistic
(p-value)n Estimate n Estimate
Clinical features
Age (years) (Median, IQR] 662 9.91 (7.1–13.1) 1010 9.5 (7.1–12.5) χ2 = 5.37 (0.020)
Pulse rate (beats/min) [mean, 95%CI] 680 90.5 (89.2–91.8) 1585 94.0 (93.2–94.7) t = − 4.79 (< 0.001)
Temperature(oc) [mean, 95%CI] 694 36.0 (35.8–36.4) 1628 36.5 (36.4–36.5) t = − 3.63 (< 0.001)
Systolic Blood pressure (mm/Hg) [mean, 95%CI] 685 107.5 (105.8–109.2) 1462 104.9 (104.1–105.6) t = 3.31 (0.001)
Diastolic blood pressure(mm/Hg) [mean, 95%CI] 684 67.5 (66.3–68.7) 1461 63.9 (63.3–64.5) t = 5.96 (< 0.001)
Peripheral Oxygen saturation,(median, IQR) 662 99 (98,100) 1010 98 (96,100) z = 11.78 (p < 0.001)
Peripheral Oxygen desaturation, [n/N (%)] 50/663 (7.5) 162/1009 (16.1) χ2 = 26.2 (p < 0.001)
Jaundice, [n/N (%)] 45/309 (14.6) 943/1541 (61.2) χ2 = 224.4 (p < 0.001)
Palpable Spleen, [n/N (%)] 25/451 (5.54) 201/1552 (12.9) χ2 = 19.16 (< 0.001)
Laboratory features (95%CI)
Hemoglobin (Hb) (g/dL) 759 10.6 (10.4–10.8) 1653 7.4 (7.3–7.4) t = 32.34 (< 0.001)
Fetal hemoglobin (HbF) 422 1.7 (0.91–2.5) 803 6.8 (6.4–7.1) t = −11.7 (< 0.001)
Mean Cell Volume (MCV) (fL) 762 75.2 (74.3–76.0) 1653 79.7 (79.1, 80.2) t = −8.72 (< 0.001)
Mean Cell Hb (MCH) (pg) 743 24.5 (24.2–24.7) 1628 26.0 (25.8–26.2) t = −9.12 (< 0.001)
Mean Cell Hb Concentration(MCHC) (g/dL) 760 32.2 (32.1–32.3) 1632 32.5 (32.4–32.6) t = −4.00 (< 0.001)
Red Cell Distribution width (RDW) (%) 761 17.3 (17.0–17.6) 1636 22.6 (22.4–22.8) t = −31.49 (< 0.001)
Reticulocyte (%) 294 7.1 (6.0–8.4) 583 11.2 (10.6–11.8) t = −6.15 (< 0.001)
Absolute reticulocyte (×109/L) 274 0.26 (0.21–0.31) 563 0.33 (0.32–0.36) t = −2.42 (0.016)
White Blood Cells (WBC) (× 109/L) 868 9.1 (8.6–9.5) 1582 15.6 (15.2–15.9) t = − 23.5 (< 0.001)
Platelets (PLT) (× 109/L) 763 349.3 (336.5–362.04) 1652 444.4 (434.5–454.3) t = − 11.55 (< 0.001)
Bilirubin total (μmol/L) 271 10.3 (9.3–11.4) 930 59.7 (56.7–62.8) t = −30.72 (< 0.001)
Bilirubin direct (μmol/L) 188 3.0 (2.5–3.6) 875 14.4 (13.6–15.2) t = −19.08 (< 0.001)
Bilirubin indirect (μmol/L) 179 8.6 (7.4–9.9) 865 42.1 (39.5–44.8) t = − 20.52 (< 0.001)
Aspartate AminoTransferase (AST) (U/L) 295 36.1 (32.6–39.5) 949 52.0 (49.7–54.5) t = −7.69 (< 0.001)
Alkaline phosphatase (ALP) (IU/L) 294 353.6 (329.5–377.7) 953 267.5 (258.8–276.5) t = 6.58 (< 0.001)
Lactate dehydrogenase (LDH) (U/L) 328 593.8 (548.0–639.5) 569 971.6 (932.0–1011.2) t = − 12.28 (< 0.001)
Creatinine (μmol/L) 292 46.8 (44.7–48.9) 949 37.6 (36.6–38.5) t = 8.36 (< 0.001)
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services throughout the country, as part of the non-
communicable diseases (NCD) program [29]. The age-
specific rate of enrollment (Fig. 1c) shows a marked de-
crease with age: this suggests, unfortunately, a high rate of
early mortality in the younger age group, which we have
previously reported [16]. At the same time, it is important
to note that 518 SCD individuals were aged ≥18 years, pro-
viding evidence of survival into adulthood and highlighting
the need for adult services. It should be noted that the adult
SCD population may comprise two distinct groups: (a)
those with severe disease seeking healthcare due to acute
and chronic complications, sometimes related to end-organ
dysfunction; (b) those with relatively mild disease, who sur-
vived childhood.
We report heterogeneity in the geographical preva-
lence of SCD in Tanzania. The enrollment into the MSC
program of patients from different parts of Tanzania will
have been influenced by ease of access for residents in
regions closer to MNH and/or by socio-economic status,
whereby those with higher income are more likely to
come to MNH. Nevertheless, it is interesting that the
highest numbers were from the coastal regions, includ-
ing Zanzibar, and from regions around Lake Victoria,
despite the long distance between these regions and
Dar-es-Salaam. These areas are known to have high mal-
aria transmission. On the other hand, there were lower
numbers from regions close to Dar-es-Salaam such as
Iringa, Manyara, Lindi, Kilimanjaro, where malaria trans-
mission is less. It is noteworthy that, in spite of the ascer-
tainment bias just mentioned, these data agree with
previous estimates of βS gene frequencies in Tanzania [1],
although further research is needed to evaluate the genetic
and environmental factors, other than malaria, that influ-
ence disease prevalence. Detailed micro-mapping of SCD
prevalence will also aid planning of optimal health ser-
vices, targeting areas with high prevalence.
In the initial analysis of features of SCD (Table 2) we
compared SCD with non-SCD (HbAA and HbAS) indi-
viduals enrolled at the same time. The purpose of this
comparison was not to illustrate the differences between
SCD and non-SCD, as by definition SCD patients, who
have life-long haemolytic anaemia would be discernably
different from the non-SCD group. We anticipated that
several parameters such as haemoglobin, reticulocytes
and bilirubin levels would be higher. What we could not
have predicted a priori was that the mean value of all pa-
rameters measured would be significantly different -
even though, in many cases by a small measure (but,
given the large numbers of individuals tested, in nearly
all cases the P-value was less than 0.001). The SCD group
when compared to non-SCD group had higher prevalence
of jaundice and higher pulse rate. The blood pressure was
lower in the SCD group, similar to previous reports of a
low prevalence of hypertension in this SCD population as
Fig. 3 Distribution of mean difference of hematological parameters between non-SCD and SCD individuals by age-group. Only mean difference
for platelets, ALP and creatinine for children < 5 years were not significant difference (*) between the non-SCD and SCD (p > 0.05)
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well as in the USA [23, 30]. The peripheral oxygen
saturation was significantly lower in SCD: the differ-
ence was small, but in 16.1% of patients it was below
95%. This may be clinically signficant because it is re-
lated to the severity of anaemia [31] and to high
2,3-DPG levels, which increases deoxy-Hb S
polymerization and sickling [32]. We and others have
previously observed that low oxygen saturation is as-
sociated with increased cerebral blood flow velocity
[33, 34], and higher risk of neurological complications
[35, 36]. It was observed that there were low levels of
red cell indices (MCV, MCH), which may be attrib-
uted in part to the high frequency of α-thalassaemia
in this population (about 40% heterozygotes [37]):
however, there is no a priori reason why this fre-
quency should be any different in SCD versus
non-SCD.
Novel information
Most studies of SCD have focused on children and
adults separately, reflecting the fact that most healthcare
systems have dedicated but separate paediatric and adult
services. The MSC program, instead, aimed to integrate
the care of SCD patients across their life span. First, we
noted that pain, infection and anaemia were the three
most common causes of hospital visits (Fig. 5): but
whereas in children the most common cause was an-
aemia, adults were more affected by painful episodes.
Table 3 Clinical and laboratory features of SCD individuals in 3 age categories (< 5 years; 5–17 years and ≥ 18 years)
Variable N Age group (years) Test statistic P-value
0–4 years 5–17 years ≥18 years
Clinical features
Age (years) (Median,IQR] 3265 2.5 (1·4–3.8) 9.5 (7.1–12.5) 23.7 (20.3–29.5)
Pulse rate (beats/min) [mean, sd] 3238 110.11 ± 23.1 94.0 ± 15.1 83.5 ± 13.7 446.3↓ < 0.001
Temperature(oc) [mean, sd] 3413 36.5 ± 1.5 36.5 ± 1.0 36.3 ± 1.8 3.16↓ 0.042
Systolic Blood pressure (mm/Hg) [mean, sd] 2993 97.9 ± 24.2 104.9 ± 14.4 116.6 ± 16.9 160.8↑ < 0.001
Diastolic blood pressure(mm/Hg) [mean, sd] 2993 58.8 ± 16.4 63.9 ± 11.5 70.7 ± 12.2 127.9↑ < 0.001
Peripheral Oxygen saturation,(median, IQR) 2713 99 (97–100) 98 (96–100) 98 (96–99) 13.7 0.001
Peripheral Oxygen desaturation, [n/N (%)] 2713 170 (15.4) 200 (16.4) 58 (14.9) 0.654 0.721
Jaundice, [n/N (%)] 3171 542 (45.0) 943 (61.2) 292 (68.4) 102.0↑ < 0.001
Pallor, [n/N (%)] 3102 447 (37.8) 573 (38.1) 142 (34.5) 2.06 0.357
Palpable Spleen, [n/N (%)] 3242 192 (15.5) 201 (12.9) 21 (4.7) 35.0↓ < 0.001
Laboratory features
Hemoglobin (Hb) (g/dL) 3456 7.2 ± 1.4 7.4 ± 1.4 7.6 ± 2.1 10.24↑ < 0.001
Fetal hemoglobin (HbF) 1942 12.2 ± 7.9 6.8 ± 5.63 5.6 ± 4.7 182.9↓ < 0.001
Mean Cell Volume (MCV) (fL) 3454 78.1 ± 11.1 79.7 ± 11.7 82.4 ± 13.8 22.49↑ < 0.001
Mean Cell Hemoglobin (MCH) (pg) 3406 24.6 ± 3.6 26.0 ± 4.1 27.2 ± 5.0 84.11↑ < 0.001
Mean Cell Hemoglobin Concentration(MCHC) (g/dL) 3419 31.4 ± 1.7 32.5 ± 2.1 32.9 ± 2.1 169.58↑ < 0.001
Red Cell Distribution width (RDW) (%) 3440 23.8 ± 4.0 22.6 ± 3.8 21.1 ± 4.4 81.22↓ < 0.001
Reticulocyte (%) 1212 13.3 ± 7.8 11.3 ± 7.5 10.3 ± 7.0 14.45↓ < 0.001
Absolute reticulocyte (×109/L) 1153 0.40 ± 0.35 0.33 ± 0.32 0.33 ± 0.62 5.06↓ 0.006
White Blood Cells (WBC) (×109/L)) 3238 19.2 ± 8.3 15.6 ± 6.6 12.4 ± 5.2 170.95↓ < 0.001
Platelets (PLT) (×109/L)) 3453 377.6 ± 19.8 444.4 ± 205 450.7 ± 213.2 45.92↑ < 0.001
Log(Bilirubin total (μmol/L)) 1706 3.62 ± 0.74 4.11 ± −.78 4.16 ± 0.81 76.3↑ < 0.001
Log(Bilirubin direct (μmol/L)) 1561 2.45 ± 0.82 2.73 ± 0.80 2.79 ± 0.90 21.3↑ < 0.001
Log(Bilirubin indirect (μmol/L)) 1545 3.28 ± 0.83 3.76 ± 0.92 3.80 ± 0.91 47.9↑ < 0.001
Aspartate Aminotransferase (AST) (U/L) 1750 53.2 ± 31.5 52.0 ± 38.3 48.2 ± 39.8 1.64 0.193
Alkaline phosphatase (ALP) (IU/L) 1758 314.2 ± 147.2 267.5 ± 140.5 179.2 ± 156.1 75.69↓ < 0.001
Lactate dehydrogenase (LDH) (U/L) 1196 962.2 ± 428.0 971.6 ± 481.1 918.4 ± 686.9 0.78↑ 0.461
Log(Creatinine (μmol/L)) 1744 3.49 ± 0.36 3.23 ± 0.39 3.94 ± 0.43 117.0↑ < 0.001
Variables (Hypoxia, Jaundice, Pallor, Palpable Spleen) were compared using χ2 test, while rest of variables were compared using F-test. ↓ Effect decrease with
increase in age while ↑ indicate increase of the effect with age
Makani et al. BMC Hematology           (2018) 18:33 Page 8 of 13
This is similar to findings in other series, where 50% of
adults experience painful episodes compared to only
10% in children [38]. Next, we analyzed by age groups
all other data over the entire age span from infancy to
adulthood. To our knowledge, this is one of the first
studies in which such a systematic analysis has been
attempted. Here we will focus only on a few observa-
tions which we think are important. First, mean level of
Hb increased with age, though only slightly, and this was
associated with a decrease in the mean reticulocyte
count. This correlation is expected, as the increased re-
ticulocyte count reflects a normal compensatory erythro-
poietic response to anaemia. The decreased reticulocyte
count in older patients with SCD may also have reflected
reduced erythropoietin levels in the context of the onset
of chronic kidney disease, as evidenced by the higher
creatinine in the older age group. An alternative explan-
ation may possibly be a direct effect of vaso-occlusive
events on the bone marrow resulting in reduced erythro-
poiesis with impaired reticulocyte production. Second,
with respect to HbF, we expected that the mean HbF
level would be highest in the youngest age group, since
the physiological decrease in HbF from the level of
about 80% at birth is much delayed in SS children –
compared to controls – in at least the first 30 months of
life [39]. However, the further decrease in HbF in the
Fig. 4 Distribution of selected laboratory parameters of SCD individuals by age-group
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transition from the 5–17 age group to adulthood is
somewhat paradoxical, because one would have expected
that SCD patients with higher HbF would be, if any-
thing, favored in terms of survival: since HbF was seen
not to predict mortality in our previous work [33], this
finding requires further research. Third, the mean values
of red cell indices (MCV, MCH, MCHC) were lower in
the younger age group which, in line with the fall in
RDW with age, may mean that iron deficiency anemia is
more common in the youngest patients (it is indeed
common in Tanzania in the < 5 age group). Low MCV
and MCH may also result from α-thalassaemia, which is
generally regarded as an ameliorating factor in SCD;
however, from these data and our previous work [33],
low MCV does not seem to confer a survival advantage.
Fourth, the mean WBC count decreased with age: which
may suggest that the prevalence of infection is higher in
children and decreases with age. However, the down-
ward trend in WBC counts may also mean that the older
age group is representative of less severe disease. In con-
trast, the mean platelet count increased with age, probably
reflecting a decrease in splenic function: this explanation
is supported by a lower prevalence of palpable spleen in
the older age groups. The age-specific patterns in the level
of WBC counts and platelets warrant further research, as
the role of these blood components in the pathophysi-
ology of SCD is being increasingly recognized [40]. Fifth,
the mean level of bilirubin increases with age, in keep-
ing with the observation that prevalence of jaundice in-
creased with age. This may be explained by an increase
in the rate of extravascular haemolysis; liver dysfunc-
tion is less likely since there was a decrease in the mean
levels of ALP and AST (albeit not statistically signifi-
cantly with respect to AST). We must also consider
that the higher levels of ALP in the younger age groups
could be related to increased bone tissue turnover asso-
ciated with growth. A striking observation was the high
level of LDH (more than 3 times the upper limit of nor-
mal) in all age groups, which suggests a significant level
of intravascular haemolysis, although cardiac and liver
dysfunction may also contribute. Further research is re-
quired to quantitate the age-specific rate of haemolysis
and whether there is a change with age in the relative
rates of intravascular versus extravascular haemolysis.
Finally, the mean creatinine level increased with age, al-
though most values remained within the normal range.
The creatinine level on its own is not a sensitive index
of early renal disease, but one wonders whether in indi-
vidual cases the trend of creatinine with age may be a
prelude to renal insufficiency, a known complication of
SCD. It should be noted that the age-related trends in
clinical and laboratory parameters in this report were
also reported by Aliyu et al. [41] in Nigeria (208 indi-
viduals with SCD; Youngest 10 years; 7% > 35 years).
Fig. 5 Conditions associated with hospital visits in the 12 months preceding enrolment visit
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In one of the first systematic studies of SCD patients,
Nagel and colleagues [42] noted that the βS haplotype
may account for the great variability in the clinical
symptomatology and severity of SCD. In this population
in Tanzania, this layer of heterogeneity is largely re-
moved, since nearly all patients are homozygous for the
Central African Republic (CAR) haplotype (previously
referred to as Bantu haplotype) [43]: However, the
spread of values remains just as great (Fig. 4); for ex-
ample, the mean hematocrit level that Nagel et al. [42]
reported for SS patients with CAR haplotype was 23.1,
which corresponds almost to the mean Hb of 7.4 in the
Tanzania population with the same haplotype, although
the range in Tanzania is wider. Although the β-globin
haplotype is regarded as a major determinant of HbF
production, we found (Fig. 4) a markedly skewed distri-
bution, whereby the top 2.5% of patients had HbF values
some 4 times higher than the mean. Genomic studies
conducted in SCD in Tanzania have already reported
variability in prevalence of and co-existence of genomic
loci that influence HbF, α-thalassemia, and G6PD levels
[25, 37]. Further research is required, and is ongoing, to
increase understanding in the complex interplay of gen-
etic, environmental and socio-economic factors influen-
cing variability of disease spectrum [44].
Limitations
Because enrolment into the SCD cohort was hospital-
based, the study may not have captured individuals with
mild disease. The non-SCD group was not a population-
based age- and sex-matched control group: rather, it was
a ‘convenient’ comparison group consisting of patient
family members and of individuals enrolled among those
suspected to have SCD: hence they may have other med-
ical conditions. Indeed, the clinical and laboratory features
were often not normal. We did not separate controls with
HbAA from those with HbAS. This is broadly justified be-
cause sickle cell trait subjects have no cells containing ex-
clusively HbS and are haematologically normal. However
it is possible that some parameters may differ in AA ver-
sus AS subjects: this requires further study. Finally, the
work reported here is that from cross-sectional analysis of
the enrolment cohort. Although the study was conducted
over a 10 year period, we are not yet presenting longitu-
dinal data.
Conclusion
This work demonstrates that in an African country it is
feasible to enrol, across all age groups, a large number of
SCD patients and to assess in considerable detail their
clinical and laboratory manifestations. Not surprisingly,
in first approximation the clinical spectrum of SCD is
similar to that observed elsewhere. However, the age dis-
tribution is different, unfortunately reflecting, at least in
part, early mortality and delayed diagnosis due to the ab-
sence of newborn screening. The prevalence of severe
anaemia is high, probably reflecting less blood transfu-
sion treatment and other environmental factors, includ-
ing malaria and a higher rate of bacterial infection.
SCD has been recognized as a major public health
problem: as such, it was essential for us to establish not
just its size, but also its spectrum. While this paper was
in its first draft the first SCD patient successfully cured
with gene therapy was reported [45] and the American
Society of Hematology issued a Call to Action on Sickle
Cell Disease. We feel strongly that in Africa the transi-
tion from taking stock to taking action is overdue: we
must implement urgently beneficial measures such as
newborn screening, infection prophylaxis, optimization
of blood transfusion practice and the use of hydroxy-
urea; and we must also contribute to research on poten-
tially curative treatments.
Abbreviations
AA: Haemoglobin AA (normal haemoglobin); ALP: Alkaline phosphatase;
AS: Haemoglobin AS (sickle cell trait); AST: Aspartate aminotransferase; BIL-
D: Bilirubin direct; BIL-T: Bilirubin total; BT: Blood transfusion; CC: Haemoglobin CC;
CRF: Case report forms; EDTA: Ethylenediaminetetraacetic acid; Hb: Haemoglobin;
HbF: Fetal haemoglobin; HPFH: Hereditary persistence of fetal haemoglobin;
HPLC: High performance Liquid Chromatography; IQR: Inter quartile range;
LDH: Lactate dehydrogenase; MCH: Mean corpuscular haemoglobin; MCHC: Mean
corpuscular haemoglobin Concentration; MCV: Mean corpuscular volume;
MNH: Muhimbili National Hospital; MSC: Muhimbili Sickle cell; MUHAS: Muhimbili
University of Health and Allied Sciences; NCD: Non-Communicable Diseases;
PLT: Platelet count; RBC: Red blood cell count; RDW: Red cell distribution width;
SC: Haemoglobin SC; SCD: Sickle cell disease; SS: Haemoglobin SS; UK: United
Kingdom; USA: United States of America; WBC: White blood cell; WHO: World
Health Organization; βS: Beta globin
Acknowledgements
We thank the patients and staff of Muhimbili National Hospital and Muhimbili
University of Health and Allied Sciences. We thank the following individuals:
Data collection: Albert N Komba, Critical comments on statistical analysis: Neal
O Jeffries, Nancy L Geller from NHLBI, NIH. Mentorship and support: Thomas
Williams, Kevin Marsh, Kisali Pallangyo, Ephata Kaaya.
Funding
This work was supported by the Wellcome Trust, UK (Fellowship Julie Makani
072064, 093727; Project grant 080025; Strategic award 084538; Principal
Wellcome Trust Fellowship R W Snow 103602) and Government of United
Republic of Tanzania.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
Contribution: JMa, RWS, CRN, DR, MA, SLT, SEC conceived and designed the
study; JMa, FT, AM, DS, SR, CK, EO and EM patients care and clinical data
collection; SN and JMg performed sample processing and laboratory analyses; RS
and SEC were responsible for data management; BPM analysed the data; JMa, LL
and BPM wrote the paper; RWS, CRN, DR, MA, SLT, FJK and SEC critically
reviewed the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Approval was by MUHAS ethical committee (MU/RP/AEC/VOL XI/33) and
permission given by MNH. Written informed consent was obtained from all
participants. For individuals 18 years or above, while for minors, a parent/
guardian consented and signed the consent on behalf of the patient; adolescents
provided assent.
Makani et al. BMC Hematology           (2018) 18:33 Page 11 of 13
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania.
2University of Oxford, Oxford, UK. 3Muhimbili National Hospital,
Dar-es-Salaam, Tanzania. 4Dar-es-Salaam University College of Education,
Dar-es-Salaam, Tanzania. 5University College London, London, UK. 6Centre for
Geographic Medicine Research, Kenya Medical Research Institute, Kilifi, Kenya.
7National Institutes of Health, Bethesda, USA. 8London School of Hygiene &
Tropical Medicine, London, UK. 9National Institute for Medical Research
Tanga Centre, Tanga, Tanzania.
Received: 11 March 2018 Accepted: 16 October 2018
References
1. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global
epidemiology of sickle haemoglobin in neonates: a contemporary
geostatistical model-based map and population estimates. Lancet. 2013;281:
142–51.
2. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited
disorders of hemoglobin. 2006.
3. Gaston M, Rosse WF. The cooperative study of sickle cell disease: review of
study design and objectives. Am J Pediatr Hematol Oncol. 1982;4:197–201.
4. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J, Newell H, et al. Clinical
outcomes in children with sickle cell disease living in England: a neonatal
cohort in East London. Haematologica. 2007;92:905–12.
5. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al. Clinical
events in the first decade in a cohort of infants with sickle cell disease.
Cooperative Study of Sickle Cell Disease. Blood. 1995;86:776–83.
6. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in
homozygous sickle cell disease: lessons from a cohort study. BMJ. 1995;311:
1600–2.
7. Diagne I, Diagne-Gueye ND, Signate-Sy H, Camara B, Lopez-Sall P, Diack-
Mbaye A, et al. Management of children with sickle cell disease in Africa:
experience in a cohort of children at the Royal Albert Hospital in Dakar.
Med Trop (Mars). 2003;63:513–20.
8. Rahimy MC, Gangbo A, Ahouignan G, Adjou R, Deguenon C, Goussanou S,
et al. Effect of a comprehensive clinical care program on disease course in
severely ill children with sickle cell anemia in a sub-Saharan African setting.
Blood. 2003;102:834–8.
9. Tshilolo L, Mukendi R, Girot R. Sickle cell anemia in the south of Zaire. Study of
two series of 251 and 340 patients followed-up 1988-1992. Arch Pediatr. 1996;
3:104–11.
10. Dubert M, Elion J, Tolo A, Diallo DA, Diop S, Diagne I, et al. Degree of
anemia, indirect markers of hemolysis, and vascular complications of sickle
cell disease in Africa. Blood. 2017;130:2215–23.
11. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell
anemia: a 4-decade observational study of 1056 patients. Medicine
(Baltimore). 2005;84: 363–76.
12. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;377:
305.
13. World Health Organisation. Sickle Cell Anaemia. Agenda item 11.4. 59th
World Health Assembly, 27 May 2006. 2006.
14. World Health Organisation. The Brazzaville declaration on non-communicable
diseases prevention and control in the WHO African region. 2011.
15. Tluway F, Makani J. Sickle cell disease in Africa: an overview of the
integrated approach to health, research, education and advocacy in
Tanzania, 2004–2016. Br J Haematol:2017;177:919–29.
16. Makani J, Cox SE, Soka D, Komba AN, Oruo J, Mwamtemi H, et al. Mortality
in sickle cell anemia in africa: a prospective cohort study in Tanzania. PLoS
One. 2011;6:e14699.
17. Makani J, Komba AN, Cox SE, Oruo J, Mwamtemi K, Kitundu J, et al. Malaria
in patients with sickle cell anemia: burden, risk factors, and outcome at the
outpatient clinic and during hospitalization. Blood. 2010;115:215–20.
18. Mmbando BP, Mgaya J, Cox SE, Mtatiro SN, Soka D, Rwezaula S, et al. Negative
epistasis between sickle and foetal haemoglobin suggests a reduction in
protection against malaria. PLoS One. 2015;10:e0125929.
19. Makani J, Mgaya J, Balandya E, Msami K, Soka D, Cox SE, et al. Bacteraemia in
sickle cell anaemia is associated with low haemoglobin: a report of 890
admissions to a tertiary hospital in Tanzania. Br J Haematol. 2015;171:273–76.
20. Cox SE, Makani J, Fulford AJ, Komba AN, Soka D, Williams TN, et al.
Nutritional status, hospitalization and mortality among patients with sickle
cell anemia in Tanzania. Haematologica. 2011;96:948–53.
21. Cox SE, Soka D, Kirkham FJ, Newton CRJ, Prentice AM, Makani J, et al.
Tricuspid regurgitant jet velocity and hospitalization in Tanzanian children
with sickle cell anemia. Haematologica. 2014;99:e1–4.
22. Cox SE, Makani J, Newton CR, Prentice AM, Kirkham FJ. Hematological and
genetic predictors of daytime hemoglobin saturation in Tanzanian children
with and without sickle cell anemia. ISRN Hematol. 2013;2013:472909.
23. Makubi A, Mmbando BP, Novelli EM, Lwakatare J, Soka D, Marik H, et al. Rates
and risk factors of hypertension in adolescents and adults with sickle cell
anaemia in Tanzania: 10 years’ experience. Br J Haematol. 2017;177:930–37.
24. Makani J, Menzel S, Nkya S, Cox SE, Drasar E, Soka D, et al. Genetics of fetal
hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood. 2011;
117:1390–2.
25. Mtatiro SN, Singh T, Rooks H, Mgaya J, Mariki H, Soka D, et al. Genome wide
association study of fetal hemoglobin in sickle cell Anemia in Tanzania.
PLoS One. 2014;9:e111464.
26. New. NBS. Geographical Information System (GIS). https://www.nbs.go.tz/
nbstz/index.php/english/geographical-information-system-gis. Accessed 30
Oct 2018.
27. Farber MD, Koshy M, Kinney TR, the Cooperative Study of Sickle Cell Disease.
Cooperative study of sickle cell disease: Demographic and socioeconomic
characteristics of patients and families with sickle cell disease. J Chronic Dis. 1985;
38:495–05.
28. King LGC, Bortolusso-Ali S, Cunningham-Myrie CA, Reid MEG. Impact of a
comprehensive sickle cell center on early childhood mortality in a
developing country: the Jamaican experience. J Pediatr. 2015;167:702-5.e1.
29. Ministry of Health and Social welfare Tanzania. In: Division of preventative
health services, editor. National Strategy for Non-Communicable Diseases
2009–2015: Tanzania Food and Nutrition Centre; 2009.
30. Pegelow CH, Colangelo L, Steinberg M, Wright EC, Smith J, Phillips G, et al.
Natural history of blood pressure in sickle cell disease: risks for stroke and death
associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102:
171–7.
31. Campbell A, Minniti CP, Nouraie M, Arteta M, Rana S, Onyekwere O, et al.
Prospective evaluation of haemoglobin oxygen saturation at rest and after
exercise in paediatric sickle cell disease patients. Br J Haematol. 2009;147:
352–9.
32. Poillon WN, Kim BC, Castro O. Intracellular hemoglobin S polymerization
and the clinical severity of sickle cell anemia. Blood. 1998;91:1777-83..
33. Makani J, Kirkham FJ, Komba A, Ajala-Agbo T, Otieno G, Fegan G, et al. Risk
factors for high cerebral blood flow velocity and death in Kenyan children
with sickle cell Anaemia: role of haemoglobin oxygen saturation and febrile
illness. Br J Haematol. 2009;145:529–32.
34. Ojewunmi OO, Adeyemo TA, Osuntoki AA, Imaga NA, Oyetunji AI.
Haemoglobin oxygen saturation, leucocyte count and lactate
dehydrogenase are predictors of elevated cerebral blood flow velocity in
Nigerian children with sickle cell anaemia. Paediatr Int Child Health. 2018;38:
34–39.
35. Setty BNY, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle
cell disease: biomarker modulation and relevance to pathophysiology.
Lancet. 2003;362:1450–5.
36. Kirkham FJ, Hewes DKM, Prengler M, Wade A, Lane R, JPM E. Nocturnal
hypoxaemia and central-nervous-system events in sickle-cell disease.
Lancet. 2001;357:1656–9.
37. Cox SE, Makani J, Soka D, L’Esperence VS, Kija E, Dominguez-Salas P, et al.
Haptoglobin, alpha-thalassaemia and glucose-6-phosphate dehydrogenase
polymorphisms and risk of abnormal transcranial Doppler among patients
with sickle cell anaemia in Tanzania. Br J Haematol. 2014;165:699–706.
38. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal.
Blood. 2012;120:3647–56.
Makani et al. BMC Hematology           (2018) 18:33 Page 12 of 13
39. Maier-Redelsperger M, Noguchi CT, de Montalembert M, Rodgers GP,
Schechter AN, Gourbil A, et al. Variation in fetal hemoglobin parameters and
predicted hemoglobin S polymerization in sickle cell children in the first two
years of life: Parisian Prospective Study on Sickle Cell Disease. Blood. 1994;84:
3182–8.
40. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, and inflammatory
pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127:
801–9.
41. Aliyu ZY, Gordeuk V, Sachdev V, Babadoko A, Mamman AI, Akpanpe P, et al.
Prevalence and risk factors for pulmonary artery systolic hypertension
among sickle cell disease patients in Nigeria. Am J Hematol. 2008;83:485–90.
42. Nagel RL, Rao SK, Dunda-Belkhodja O, Connolly MM, Fabry ME, Georges A,
et al. The hematologic characteristics of sickle cell anemia bearing the
Bantu haplotype: the relationship between G gamma and HbF level.
Blood. 1987;69:1026–30.
43. Nagel RL, Ranney HM. Genetic epidemiology of structural mutations of the
beta-globin gene. In: Seminars in hematology; 1990;342–59.
44. Makani J, Ofori-Acquah SF, Tluway F, Mulder N, Wonkam A. Sickle cell
disease: tipping the balance of genomic research to catalyse discoveries in
Africa. Lancet. 2017;389:2355–58.
45. Ribeil J-A, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E,
et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;
376:848–55.
Makani et al. BMC Hematology           (2018) 18:33 Page 13 of 13
